September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
The protective effect of activated protein C (APC) on cell permeability and laser-induced CNV progression
Author Affiliations & Notes
  • Iris Deitch
    Department of Ophthalmology, Rabin Medical Center, PetachTikva, Israel
  • Tilda Barliya
    Laboratory of Eye Research, Felsenstein Medical Research Center, Rabin Medical Center, PetachTikva, Israel
  • Omer Bialer
    Department of Ophthalmology, Rabin Medical Center, PetachTikva, Israel
    Laboratory of Eye Research, Felsenstein Medical Research Center, Rabin Medical Center, PetachTikva, Israel
  • Yael Nisgav
    Laboratory of Eye Research, Felsenstein Medical Research Center, Rabin Medical Center, PetachTikva, Israel
  • Mor Dachbash
    Laboratory of Eye Research, Felsenstein Medical Research Center, Rabin Medical Center, PetachTikva, Israel
  • Dov Weinberger
    Department of Ophthalmology, Rabin Medical Center, PetachTikva, Israel
    Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
  • Tami Livnat
    Laboratory of Eye Research, Felsenstein Medical Research Center, Rabin Medical Center, PetachTikva, Israel
    Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
  • Footnotes
    Commercial Relationships   Iris Deitch, None; Tilda Barliya, None; Omer Bialer, None; Yael Nisgav, None; Mor Dachbash, None; Dov Weinberger, None; Tami Livnat, None
  • Footnotes
    Support  Claire and Amédée Maratier Institute for the Study of Blindness and Visual Disorders
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 2141. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Iris Deitch, Tilda Barliya, Omer Bialer, Yael Nisgav, Mor Dachbash, Dov Weinberger, Tami Livnat; The protective effect of activated protein C (APC) on cell permeability and laser-induced CNV progression. Invest. Ophthalmol. Vis. Sci. 2016;57(12):2141.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Choroidal neovascularization (CNV) is the leading cause of severe vision loss in various ocular diseases such as age-related macular degeneration (AMD), angioid streaks and high myopia. A rupture of Bruch’s membrane which follows by a damage to the blood retinal barrier (BRB) induces CNV formation and progression. Activated protein C (APC) is a plasma serine protease with systemic anticoagulant, anti-inflammatory and antiapoptotic activity. Our aim is to explore the barrier protective effect of APC treatment in both an in vitro and a laser-induced CNV animal models.

Methods : In vitro model: human retinal pigment epithelial cells (ARPE-19) were cultured for a month to achieve definite polarity properties. APC-induced cell permeability was evaluated based on spectrophotometric monitoring of the transport across the cell layer of labeled dextran. Cellular localization of the tight junction protein Zonula Occludens 1 (ZO-1) was studied using immunofluorescence staining with anti-ZO1 antibody. In vivo model: CNV was induced by indirect diode laser photocoagulation on male C57BL/6J mice. Immediately following injury mice were injected intravitreally with 1µl APC at 1µg/animal or 1µl bevacizumab at 25 µg/animal. CNV area of flat choroid was determined by using anti CD31 antibody immunofluorescence staining on days 5 and 14 post laser injury. CNV area was evaluated by image J.

Results : In vitro: APC induced translocation of ZO-1 protein to the ARPE-19 cell membrane and reduced RPE permeability as compared to untreated cells. In vivo: APC treatment dramatically reduced CNV area. The CNV area on days 5 and 14 post laser application, as indicated by CD31 staining was 34% and 50%, respectively as compared to untreated control eyes. APC effect was to a similar extant as compared to bevacizumab outcome.

Conclusions : APC was found to reduce cell permeability in RPE cells, and change the re-organization of ZO1 into a membranal position. This is the first study to show that intravitreal injection of APC lead to a significant reduction in CNV area compared to the treatment of choice, bevacizumab. This study offers an innovative approach that may lead to the development of novel therapeutic strategies targeting CNV. APC should be considered as a good candidate for such strategies though future studies are warrant to fully explore its beneficial potential.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×